Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.

Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.

Proton Therapy (Radiation Therapy)

Photon Therapy (Radiation Therapy)

Site Public Contact

Pretesh R. Patel

Jason K. Molitoris

Theodore S. Hong

John M. Robertson

Jordan Kharofa

Lauren E. Henke

Eugene J. Koay

Smith Apisarnthanarax

Theodore Hong

This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.

PRIMARY OBJECTIVES:

I. To determine if Overall Survival (OS) is different for hepatocellular carcinoma patients treated with protons compared to photons.

SECONDARY OBJECTIVES:

I. To determine the difference in Progression-Free Survival (PFS) in patients with hepatocellular carcinoma (HCC) treated with protons compared to patients with HCC treated with photons.

II. To determine the difference in local progression (LP) in patients with HCC treated with protons compared to patients with HCC treated with photons.

III. To determine differences in toxicity in patients with HCC treated with protons versus photons.

IV. To determine differences in fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue in patients with HCC treated with protons, versus photons; as well as quality-adjusted survival, if the primary endpoint is met.

V. To determine if there are correlations between the baseline values of HGF and outcomes (OS/PFS/fatigue).

EXPLORATORY OBJECTIVES:

I. To determine differences in overall Quality of Life, measured by FACT-Hep in patients with HCC treated with protons.

II. Biospecimen collection for future correlative science projects.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.

ARM II: Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.

After completion of study treatment, patients are followed every 3 months for 2 years, and then every 6 months for 3 years.

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma

OS will be estimated by the Kaplan-Meier method. The distributions of OS between treatment arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.

PFS is defined as local/regional/distant progression or death due to any cause and will be estimated by the Kaplan-Meier method. The distributions of PFS between treatment arms will be compared using the log rank test.

LP will be estimated by the cumulative incidence method and compared using Gray's test. The Fine-Gray regression model will be used to analyze the effects of factors, in addition to treatment, which may be associated with LP.

A Chi-square test will be used to compare the number of patients with at least 1 grade 3 or higher adverse events between the treatment arms.

Change in fatigue will be compared between treatment arms using a t-test. If the data do not satisfy the normality assumption, a Wilcoxin test may be used instead.

HGF will be dichotomized at 2311 pg/mL and evaluated for prognostic significance using Cox regression model.

The EuroQol (EQ-5D) will be used to assess quality-adjusted survival.

QOL will be measured by the FACT-Hep v 4. An improvement in the FACT-HEP, defined as an increase of 5 points, will be assessed.

National Cancer Institute (NCI)

NRG Oncology

Rare Diseases

Ependymoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neuroepithelioma

Amino Acids

Fluorodeoxyglucose F18

Radiopharmaceuticals

Methionine

Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.

Participants may receive one or both: Photon therapy or proton therapy.

Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization.

Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.

Participants may receive one or both: Photon therapy or proton therapy.

Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization.

Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.

Participants may receive one or both: Photon therapy or proton therapy.

Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization.

Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is \>36 months at time of enrollment to \<21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.

Participants may receive one or both: Photon therapy or proton therapy.

Participants receive \^1\^8F-fluorodeoxyglucose and \^1\^1C-methionine to aid in tumor visualization.

Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.

Irradiation

When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.

Surgery

This is a contrast media that will be given intravenously to aid in tumor visualization.

^1^8F-Fluorodeoxyglucose

^1^1C-methionine

Participants will receive one or both: Photon or proton therapy.

Photon therapy

Proton therapy

Thomas E. Merchant, DO, PhD

The primary purpose of this study is to investigate whether surgery and re-irradiation will help treat ependymoma that has come back after initial treatment. The combined doses of the first and second courses of radiation are higher than what is usual standard of care. The investigators will study the effects and side effects of surgery and re-irradiation. They will also evaluate and study tumor tissue and blood to learn more about the tumor and how it does or does not respond to treatments and will use magnetic resonance imaging (MRI) and positron emission tomography (PET) scans to see if they can predict tumor response and tumor recurrence.

Participants will be followed for up to 5 years following enrollment. Evaluations during radiation therapy will be done weekly while receiving therapy for up to 7 weeks. Other evaluations will be done at enrollment, every 4 months from enrollment through 3 years, and every 6 months during the 4th and 5th year.

Stratification for treatment will be determined when radiation therapy planning is initiated. Patients will be stratified for outcome according to diagnosis and prior therapy.

* Stratum 1 (initial pattern of failure is local); disease confined to primary site; age \>12 months at time of enrollment to \< 21 years. Treatment: focal irradiation.
* Stratum 2 (initial pattern of failure is metastatic); neuraxis metastatic disease without equivocal evidence of local failure; age \> 36 months at time of enrollment to \< 21 years. Treatment: craniospinal irradiation.
* Stratum 3 (Initial pattern of failure is both local and metastatic): neuraxis metastatic disease with unequivocal evidence of local failure; age \> 36 months at time of enrollment to \< 21 years. Treatment: craniospinal irradiation.
* Stratum 4 (initial pattern of failure is local): disease confined to primary site, age \>36 months at time of enrollment to \<21 years; tumor shows presence of 1g gain. Treatment: craniospinal irradiation (optional).

PRIMARY OBJECTIVE:

* To prospectively estimate the progression-free and overall survival distributions for children and young adults with recurrent ependymoma treated with a second course of irradiation while monitoring for excessive central nervous system necrosis.

SECONDARY OBJECTIVES:

* To explore potential associations of clinical and treatment factors with the incidence and severity of neurological, endocrine and cognitive deficits in children and young adults with ependymoma treated with a second course of irradiation.
* Using specific measures of sleep quality, excessive daytime sleepiness, daytime activity, fatigue, symptom distress, and quality of life, explore associations of sleep, fatigue and quality of life with other measures of CNS effects, clinical and treatment factors in children and young adults with ependymoma treated with a second course of irradiation.
* To evaluate and explore differences in physical performance and movement in children and young adults with ependymoma treated with a second course of irradiation.
* Estimate and compare the response of residual tumor and the incidence and severity of structural, physiological, and vascular effects of normal brain in children and young adults with ependymoma after treatment with a second course of irradiation using specific methods of diffusion, contrast-enhancement, magnetization transfer, vascular and functional neuroimaging, and explore the association between these and other measures of CNS effects and clinical and treatment factors. Determine the time course of gray matter and white matter tract injury and recovery post irradiation and the association between imaging metrics derived from serial quantitative neural imaging and radiation dosimetry as well as neuro-cognitive outcomes.

Other Pre-Specified (Exploratory) Objectives:

* Estimate the avidity of ependymoma to 18F-fluorodeoxyglucose (FDG) and 11C-methionine positron emission tomography (IND # 104987) prior to radiation therapy and correlate change in avidity 12, 24 and 36 months after a second course of irradiation with tumor progression.
* Measure growth factor and cytokine responses in children and young adults with ependymoma after treatment with a second course of irradiation, and explore associations between these and other measures of CNS effects and clinical and treatment factors. Descriptively compare findings for patients treated with an initial course of irradiation.
* To conduct a variety of exploratory molecular analyses on tumor samples (and blood where a germline control is required), including but not limited to broad (genome-wide / array-based) or focused (gene-specific) analyses at the DNA, RNA, or protein level and next generation (whole genome, exome, transcriptome) sequencing in an effort to improve the investigators understanding of ependymoma biology, and to explore associations between molecular findings and treatment response and various side effects including vasculopathy, hearing loss, cognitive deficits, and growth hormone deficiency and other measures as appropriate.
* To explore the association of chemotherapy given prior to re-irradiation with progression-free survival and overall survival distributions
* To compare the progression-free and overall survival distributions for children (age \>3 years) and young adults with recurrent ependymoma and 1g gain treated with a second course of irradiation (focal or craniospinal) while monitoring for excessive central nervous system necrosis.

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

Baseline is the last FDG-PET and MET-PET prior to initiation of radiation therapy.

Correlation of avidity of ependymoma to 18F-fluorodeoxyglucose and 11C-methionine PET prior to radiation therapy with progression-free survival will be reported

Association between necrosis measured with MET/FDG vs. MRI Baseline is defined as day 1 of radiation therapy (RT).

Baseline is defined as day 1 of radiation therapy.

Evaluate will be of genetic variations in germline associated with treatment response and side effects. P-values will be reported.

Baseline is defined as day 1 of radiation therapy.

Evaluation will be in children and young adults with ependymoma treated with a second course of irradiation.

Outcomes will be reported by p-values.

Evaluation will be in children and young adults with ependymoma treated with a second course of irradiation.

Outcome will be reported with p values.

Evaluation will be in children and young adults with ependymoma treated with a second course of irradiation.

Outcome will be reported with p-values.

Baseline is defined as day 1 of radiation therapy.

Measured task sets: BOT2 (4-21 years old) and PPT (≥22 years old).

* BOT2 outcome: total motor composite, a standardized score range from 20 to 80, with a mean of 50 and a standard deviation of 10.
* PPT (7-item questionnaire) outcome: a score range from 0 to 28. The normative data is available from the human performance lab.

The above scores will be standardized into z-scores/T-scores for data analysis based on normative data.

Baseline is defined as day 1 of radiation therapy.

Self-reported instruments (PROMIS): Three questionnaires.

* Pediatric Physical Function - Mobility - SF1: 8-item questionnaire with the score range from 0 to 32.
* Pediatric Physical Function - Upper Extremity - SF1: same as above.
* Physical Function - SF1: 10-item questionnaire with the score range from 0 to 50.

The above scores will be standardized into z-scores/T-scores for data analysis based on normative data

Baseline is defined as day 1 of radiation therapy

Baseline is defined as day 1 of radiation therapy.

Ankle dorsiflexion active and passive range of motion: measured by goniometer, and recorded as an angle (degree).

Baseline is defined as day 1 of radiation therapy.

Overall flexibility: measured by sit and reach test, and recorded as a length (cm).

Baseline is defined as day 1 of radiation therapy.

Balance measured by Measured by sensory organization test (SOT), and the result from the test is the equilibrium score, a percentage range from 0% to 100%, with the higher percentage, the better balance. The outcome is a binary variable with a cutoff score of \< 70% indicates future risk for a fall.

Baseline is defined as day 1 of radiation therapy.

Fine motor coordination (finger and hand coordination). Measured by Composite Cerebellar Functional Severity Score (CCFS), and the outcome is an age-adjusted z-score and log transformed.

Baseline is defined as day 1 of radiation therapy.

Overall coordination measured by brief ataxia rating scale (five-item questionnaire). The outcome is a total scale range from 0 to 22.

Baseline is defined as day 1 of radiation therapy.

Lower extremity strength measured by BiodexIII. The outcomes are peak torque value/body weight ratios at different speeds of motion.

The scores will be standardized into z-scores for data analysis based on normative data.

Baseline is defined as day 1 of radiation therapy.

Hand grip strength is measured by a Jamar hand held dynamometer and recorded in kilograms (kg).

The scores will be standardized into z-scores for data analysis based on normative data.

Baseline is defined as day 1 of radiation therapy.

Resting energy expenditure is measured with indirect calorimetry after an overnight fast and recorded as REE (kcal/day).

The scores will be standardized into z-scores for data analysis based on normative data.

Baseline is defined as day 1 of radiation therapy.

Cardiopulmonary exercise test (CPET) will be completed on a treadmill using the Balke protocol or cycle ergometer using an incremental ramping protocol. The outcome is recorded as VO2max (ml/kg/min).

The scores will be standardized into z-scores for data analysis based on normative data.

Baseline is defined as the last MRI prior to initiation of radiation therapy.

This outcome will be evaluated by neuroimaging. Baseline is defined as day 1 of radiation therapy.

St. Jude Children's Research Hospital

Wounds and Injuries

Behaviors and Mental Disorders

Neoplasms, Radiation-Induced

Quality of Life

No intervention

Neige Journy, PhD

Beate Timmermann, MD

Sofie Isebaert

Karin Haustermans

An Michiels

Sandra Jacobs

Anne Uyttebroeck

Karen Van Beek

Melissa Christiaens

Yasmin Lassen

Sanja Karabegovic

Louise Tram Henriksen

Juliette Thariat, MD

Fernand Missohou, MD

Jeanne Riverain, MD

Jordan Bouter, MD

Stéphanie Bolle

Brice Fresneau

Nadia Haddy

Valentine Martin

Martina Wette

Beate Timmermann

Stéphanie Bolle, MD

Isabelle Thierry-chef, PhD

The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry complemented by a biobank.

Specific objectives:

* To develop the infrastructure and instruments for setting-up a European, long-term registry of paediatric patients treated with contemporary techniques of modern external radiotherapy;
* To assess the incidence and severity of late health outcomes, primarily endocrine dysfunctions, cardiovascular toxicities, neurovascular damages, and subsequent primary neoplasms, in relation to the dose-volume distribution to non-targeted organs and tissues, radiation delivery technique and beam quality factors, and potential modifying factors (i.e. age at exposure, genetic predispositions, comorbidities, and systemic treatments including chemotherapy, targeted therapy, immunotherapy and hormonal drugs) that may underlie differences in individual susceptibility for these outcomes ;
* To assess societal aspects of advances in radiotherapy, primarily health-related quality of life and academic achievement, in paediatric patients treated with modern external radiotherapy techniques.

Secondary scientific objectives:

* To assess multidimensional fatigue in paediatric patients treated with modern external radiotherapy techniques, and identify clinical and therapeutic determinants of fatigue;
* To improve estimation of patient-specific doses to the whole body and non-targeted organs and substructures from different radiotherapy delivery techniques;
* To investigate radiation-induced cellular responses and biological mechanisms related to the occurrence of vascular diseases and subsequent primary neoplasms in samples of blood and saliva ; to identify biomarkers of susceptibility and health effects ; to evaluate differences in disease biomarkers in relation to the radiation delivery technique and beam quality factors ; to explore the relevance of the use of saliva as a biosampling method for paediatric cohorts regarding feasibility and the quality and reproducibility for different measured biomarkers.

Secondary strategic objectives:

* To promote sustained collaborative research activities for improvement of patient care, and inform health care providers and policy makers on the clinical and social impact of advances in radiotherapy in paediatric settings;
* To serve as a pilot for a future long-term pan-European registry of children and adolescents treated with particle and photon beam therapy, including a biobank of saliva and blood samples collected before and after treatment;
* To contribute in future collaborative projects with existing cohorts or registries in Europe
* To contribute in future international research studies on late outcomes of modern radiotherapy techniques for management of paediatric cancers

Funding: The HARMONIC project has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 847707.

blood plasma; blood serum; lymphocytes; saliva

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)

Late health outcomes

* Neurovascular diseases
* Second and subsequent primary neaoplasms

measured as:

1. insulin-like growth factor-1,
2. anterior pituitary hormones (GH, ACTH, TSH, LH, FSH),
3. thyroid hormones (fT3, fT4),
4. sexual hormones

measured as blood markers (incl. troponin, BNP, CPK)

measured as cardiac echography parameters (incl. ejection fraction, diastolic function)

measured as scoring of large and small vessel damages

measured as signal quality of protein activity

measured as markers of oxidative stress (incl. 8-oxo-dG, SOD2, DNA repair enzymes)

Inflammatory markers (incl. PTX3, CRP, NF-kB, IL-1 and IL10)

Markers of carcinogenesis (incl. leukocyte telomere length, mitochondrial DNA copy number, circulating microRNA)

PedsQL™ multidimensional fatigue scale (validated questionnaire)

Barcelona Institute for Global Health

The West German Proton Therapy Centre, Essen

Gustave Roussy, Cancer Campus, Grand Paris

Centre Francois Baclesse

KU Leuven

University of Aarhus

Princess Maxima Center for Pediatric Oncology

University Medical Center Groningen

Stockholm University

National Research Council, Institute of Clinical Physiology, Italy

University of Zurich

Commissariat A L'energie Atomique

Luxembourg Institute of Science and Technology

University Hospital, Essen

Aarhus University Hospital

Institut National de la Santé Et de la Recherche Médicale, France

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Androgens

Radiation: Proton Therapy 78 Gray (Gy) in 39 fractions with 56 Gy to the Pelvic Lymph Nodes (LN), 5 days a week.

Androgen Deprivation Therapy (ADT) for three years, starting 3 months before Proton Therapy.

Radiation: Photon Therapy 78 Gy in 39 fractions with 56 Gy to the pelvic LN, 5 days a week. ADT for three years, starting 3 months before Photon Therapy.

Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.

Patients in the photon arm will receive standard treatment with photon therapy.

Lise Bentzen

Stine Petersen, MD

Lise Bentzen, MD. Ph.d.

Peter Petersen, MD. Ph.d.

Henriette LIndberg, MD.Ph.d.

Steinbjørn Hansen, MD.Ph.d

Christine Madsen, MD Ph.d.

Redas Trapiakas, MD. Ph.d.

Lise Bentzen, MD.Ph.d

The purpose of this study is to assess late gastro-intestinal side-effects comparing proton therapy to photon therapy in high-risk prostate cancer patients receiving whole pelvic irradiation.

Proton therapy (PT) is a radiation technique with possibility to spare normal pelvic organs: bladder, rectum and bowel for PC patients.

Most PC patients treated with PT receive PT to the prostate gland alone. With PT, we aim to examine PC patients in high risk with both lymph node and prostate treatment will experience less late side effects with PT compared to photon treatment.

The investigators propose a national open-labelled phase III randomized controlled trial (RCT) of proton therapy versus photon therapy of the prostate including the regional elective LN for localized/locally advanced prostate cancer patients combined with androgen deprivation therapy (ADT) aimed at 3 years. The investigators aim at reducing gastro-intestinal toxicity grad 2 more than 5 points, which is considered clinical significant, measured by mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) bowel scores at 24 months and improve HRQOL. Secondary endpoints include morbidity, quality of life and survival data up to 10 years after treatment.

A randomized phase 3 study, randomizing 1:1 between photon vs. proton therapy for prostate cancer patients with high risk disease

Protons vs. Photons for High-risk Prostate Cancer

Lymph Node Radiation Therapy With Integrated Boost to Prostate for High-risk Prostate Cancer A Randomized Phase 3 Trial Comparing Photons vs. Protons

Patient Reported Outcome The investigators aim at reducing gastro-intestinal toxicity grad 2 more than 5 points, which is considered clinically significant, measured by mean points, which is considered clinically significant.

Physician Assessed Toxicity Number of Participants With Treatment-Related Adverse events as assessed by CTCAE v5.0

Patient Reported Outcome using on-line questionnaire to assess this outcome measure

Patient Reported Outcome using on-line questionnaire to assess this outcome measure.aim at reducing gastro-intestinal toxicity grad 2 more than 5 points, which is considered clinically significant, measured by mean points, which is considered clinically significant

Patient Reported Outcome General health related quality of life (QoL) at year 2, 5 and 10 (EORTC QLQ-C30)

Rigshospitalet, Denmark

Odense University Hospital

Aalborg University Hospital

Sygehus Lillebaelt

Herlev and Gentofte Hospital

Naestved Hospital

Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro and UMC Groningen.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer	NCT03186898	Unrectable or L...	Proton Therapy ... Photon Therapy ...	18 Years -	NRG Oncology
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma	NCT02125786	Ependymoma	Irradiation Surgery ^1^8F-Fluorodeo... ^1^1C-methionin... Photon therapy Proton therapy	1 Year - 21 Years	St. Jude Children's Research Hospital
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy	NCT04746729	Neoplasms	No intervention	- 22 Years	Institut National de la Santé Et de la Recherche Médicale, France
Protons vs. Photons for High-risk Prostate Cancer	NCT05350475	Prostate Cancer Radiotherapy Si...	Proton therapy Photon therapy	18 Years -	University of Aarhus
Short Term Outcomes After PRoton And photoN radiOtherapy for IDH Mutated Grade 2 and 3 Gliomas	NCT06180434	Glioma Radiotherapy; C...		18 Years -	Erasmus Medical Center
Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer	NCT02731001	Non-Small Cell ...	Proton therapy Photon therapy	18 Years - 70 Years	Technische Universität Dresden
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy	NCT04746729	Neoplasms	No intervention	- 22 Years	Institut National de la Santé Et de la Recherche Médicale, France
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence	NCT00915005	Non-Small-Cell ...	Photon Therapy Proton Therapy Paclitaxel Carboplatin	18 Years - 85 Years	M.D. Anderson Cancer Center
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma	NCT02125786	Ependymoma	Irradiation Surgery ^1^8F-Fluorodeo... ^1^1C-methionin... Photon therapy Proton therapy	1 Year - 21 Years	St. Jude Children's Research Hospital
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence	NCT00915005	Non-Small-Cell ...	Photon Therapy Proton Therapy Paclitaxel Carboplatin	18 Years - 85 Years	M.D. Anderson Cancer Center
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer	NCT03186898	Unrectable or L...	Proton Therapy ... Photon Therapy ...	18 Years -	NRG Oncology

Spots Global Cancer Trial Database for photon therapy